LivaNova (NASDAQ:LIVN) Stock Bumped Down to Buy by Wall Street Zen

Wall Street Zen downgraded shares of LivaNova (NASDAQ:LIVN) from a strong-buy rating to a buy rating in a research note published on Saturday morning,Wall Street Zen reports.

Other equities analysts have also issued research reports about the stock. Robert W. Baird increased their price target on shares of LivaNova from $95.00 to $111.00 and gave the company an “outperform” rating in a research report on Thursday. Stifel Nicolaus set a $85.00 price objective on shares of LivaNova in a research report on Wednesday, August 5th. Needham & Company LLC boosted their target price on shares of LivaNova from $93.00 to $112.00 and gave the company a “buy” rating in a research note on Wednesday. Jefferies Financial Group reissued a “buy” rating on shares of LivaNova in a research report on Wednesday. Finally, Weiss Ratings raised shares of LivaNova from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, October 27th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, LivaNova presently has an average rating of “Moderate Buy” and an average target price of $99.56.

LivaNova Stock Down 1.3%

Shares of NASDAQ:LIVN opened at $89.99 on Friday. The company has a market capitalization of $4.96 billion, a PE ratio of 30.00 and a beta of 0.91. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.46 and a quick ratio of 1.21. The business has a fifty day moving average price of $79.27 and a two-hundred day moving average price of $73.54. LivaNova has a 1 year low of $49.73 and a 1 year high of $99.38.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, November 4th. The company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.06 by $0.17. The firm had revenue of $393.15 million during the quarter, compared to analyst estimates of $381.13 million. LivaNova had a return on equity of 16.10% and a net margin of 13.01%. The business’s revenue was up 9.9% compared to the same quarter last year. During the same period last year, the firm posted $1.11 EPS. Analysts forecast that LivaNova will post 3.79 earnings per share for the current year.

Insider Activity

In other LivaNova news, Director Francesco Bianchi sold 3,500 shares of the company’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $78.01, for a total transaction of $273,035.00. Following the sale, the director directly owned 4,434 shares of the company’s stock, valued at $345,896.34. This represents a 44.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Brooke Story sold 2,300 shares of the company’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $81.42, for a total transaction of $187,266.00. Following the sale, the director directly owned 7,488 shares in the company, valued at approximately $609,672.96. This trade represents a 23.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 7,450 shares of company stock valued at $591,839. 0.35% of the stock is currently owned by insiders.

Institutional Trading of LivaNova

A number of institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. raised its holdings in LivaNova by 1.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 81,701 shares of the company’s stock valued at $6,250,000 after acquiring an additional 847 shares during the period. AlphaCore Capital LLC purchased a new stake in shares of LivaNova during the third quarter worth $308,000. Hohimer Wealth Management LLC boosted its holdings in shares of LivaNova by 5.4% in the third quarter. Hohimer Wealth Management LLC now owns 4,277 shares of the company’s stock worth $327,000 after acquiring an additional 219 shares during the period. Alamar Capital Management LLC bought a new position in shares of LivaNova in the third quarter worth $1,814,000. Finally, Covestor Ltd boosted its holdings in shares of LivaNova by 135.1% in the third quarter. Covestor Ltd now owns 1,300 shares of the company’s stock worth $99,000 after acquiring an additional 747 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About LivaNova

LivaNova PLC (NASDAQ: LIVN) is a medical technology company that develops and manufactures devices and therapies for patients with neurological and cardiovascular conditions. Its products are used by hospitals, physicians and other healthcare providers in markets around the world.

The company’s Neuromodulation business is best known for VNS Therapy, which uses an implanted device to deliver electrical stimulation to the vagus nerve. The therapy is used primarily for drug-resistant epilepsy and treatment-resistant depression, subject to applicable regulatory approvals.